An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects

Trial Profile

An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs GSK 2647544 (Primary) ; GSK 2647544 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
    • 20 Dec 2013 Planned end date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
    • 21 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top